Estimating the social and economic benefits of pharmaceutical innovation: modeling clinical trial results in hiv disease

Abstract

The change from using clinical endpoints to surrogate marker endpoints in antiretroviral (ARV) trials for human immunodeficiency virus (HIV) disease, combined with the multiplicity of factors that may influence the effectiveness of ART in the community, requires the systematic integration of data through mathematical modeling in order for these data to be useful for most decision makers. Many issues must be considered in the construction of such models, but once constructed the models may be used to compare the expected value, epidemiological, and budget impacts of competing therapies and programs to help select the most cost effective approaches given local conditions.

Citation

Simpson, K., Voit, E., Goodman, R. and Chumney, E. (2001), "Estimating the social and economic benefits of pharmaceutical innovation: modeling clinical trial results in hiv disease", Farquhar, I., Summers, K. and Sorkin, A. (Ed.) Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development, Vol. 14), Emerald Group Publishing Limited, Leeds, pp. 175-196. https://doi.org/10.1016/S0194-3960(01)14008-4